Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial
Timolol
+ Placebo
Hemangioma+1
+ Neoplasms
+ Neoplasms by Histologic Type
Treatment Study
Summary
Study start date: March 1, 2014
Actual date on which the first participant was enrolled.A multicentric, randomized, double-blind, placebo-controlled, phase II clinical trial to evaluate the efficacy and safety of 0.5% timolol maleate solution for the early treatment of infantile hemangioma. Patients with less of 60 days of life with focal or segmental hemangiomas, superficial, mixed or abortive will be treated with topical timolol 0.5% twice a day for 24 weeks. Changes in lesion size, color and thickness will be evaluated from photographs taken at 2,4,8,12,24 and 36 weeks. Vital signs and side effects will be recorded at each visit. Response to treatment will be evaluated by a blinded investigator in a semiquantitative scale (complete resolution, improve, stabilization, worsening).
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.70 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Written informed consent for study participation and the use of the patient's photographs from the patient's parent(s) or guardian(s), * The patient is between 10 and 60 days of age at the time of enrollment, * The patient should have: * at least one focal or segmental hemangioma, mixed or superficial, present anywhere on the body of at least 0.3 cm of minimum diameter and not greater of 5 cm. * abortive or minimal growth hemangioma * Infantile hemangioma precursors Exclusion Criteria: * Patients \> 60 days of age * Complicated hemangiomas (life-threatening, function-threatening, or ulcerated) * Children who have previously received systemic, intra-lesional or topical corticosteroids, imiquimod, vincristine, alpha-interferon, propranolol or other beta blockers, PDL laser. * Patients with PHACES, LUMBAR, SACRAL or PELVIS syndrome. * Internal involvement hemangiomas (liver, GI tract, larynx) * Children with a personal history of asthma or cardiac conditions that may predispose to heart block. * Children with congenital birth defects * Children with Cancer (leukemia, sarcoma, neuroblastoma, retinoblastoma) * Children with a history of hypersensitivity to beta blockers or excipients.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
Hospital de la Santa Creu i Sant Pau
Barcelona, SpainOpen Hospital de la Santa Creu i Sant Pau in Google MapsHospital Virgen del Rocío
Seville, Spain